Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU a step closer to defining nanomaterials

This article was originally published in RAJ Devices

Executive Summary

The European Commission has launched a public consultation on the definition of the term "nanomaterials" now that its Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has published a preliminary opinion on the matter1,2. The consultation aims to achieve a science-based working definition, which is viewed as critical for the development of policy and regulatory activities on nanotechnologies, including nanomedicine. The deadline for submitting comments is 15 September.

You may also be interested in...



Regulatory Measures Could Mitigate Coronavirus Risks In Europe

As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.

Belgium’s Amophar Acquires Patch Pharma, Launches Pharmacy-Only CBD

Amophar has snapped up Belgian player Patch Pharma and at the same time launched the first pharmacy-only CBD available in the country.

Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020
UsernamePublicRestriction

Register

SC096191

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel